Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H25NO |
Molecular Weight | 283.4079 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCC[C@@]13CCN(CC=C)[C@@H]2CC4=C3C=C(O)C=C4
InChI
InChIKey=OZYUPQUCAUTOBP-QXAKKESOSA-N
InChI=1S/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1
Molecular Formula | C19H25NO |
Molecular Weight | 283.4079 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Levallorphan (brand name Lorfan), is an opiate antagonist of morphine family. Levallorphan was formerly used in general anesthesia, mainly to reverse the respiratory depression produced by opioid analgesics and barbiturates used for induction of surgical anaesthesia whilst maintaining a degree of analgesia. Levallorphan was also used in combination with opioid analgesics to reduce their side effects, mainly in obstetrics. The combination of levallorphan with pethidine was used so frequently, a standardized formulation was made available, known as Pethilorfan, by Roche Products Ltd in later 1950s. Is known to be used for narcotic overdose. Levallorphan is similar to naloxone but differs from naloxone in that it also possesses some agonist properties. It acts as an antagonist and partial agonist of the mu opioid receptor (MOR). Levallorphan can produce severe mental reactions at sufficient doses including hallucinations, dissociation, and other psychotomimetic effects, dysphoria, anxiety, confusion, dizziness, disorientation, derealization, feelings of drunkenness, and bizarre, unusual, or disturbing dreams.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35372|||G8XRH8|||Q5TDA1|||Q9UN57 Gene ID: 4988.0 Gene Symbol: OPRM1 Target Organism: Homo sapiens (Human) |
1.12 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Lorfan Approved UseUnknown |
|||
Secondary | Lorfan Approved UseUnknown |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 0.65 uM] | ||||
yes [IC50 >50 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of Innovar and innovar plus nitrous oxide on muscle tone and "H" reflex. | 1971 Sep-Oct |
|
Mechanism of morphine-induced miosis in the dog. | 1975 Feb |
|
Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. | 1995 Sep |
|
Evidence for a peripheral mechanism in cardiac opioid withdrawal. | 2001 Sep |
|
Discrimination of a single dose of morphine followed by naltrexone: substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence. | 2003 Mar |
|
Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine, and saline. | 2004 Jul |
|
Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes. | 2004 Jun 16 |
|
Determination of dextromethorphan and its metabolite dextrorphan in human urine using high performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry: a study of selectivity of a tandem mass spectrometric assay. | 2005 Feb 25 |
|
Electron ionization mass spectra of ephedrines in a doping confirmatory procedure: a curious migration of the trimethylsilyl group in the N-acetyl-O-trimethylsilyl derivatives. | 2007 |
|
Biofilm induced tolerance towards antimicrobial peptides. | 2008 Apr 2 |
|
Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. | 2008 Jan 1 |
|
A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study. | 2009 Nov |
|
Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan. | 2010 Jan |
|
Generation of novel radiolabeled opiates through site-selective iodination. | 2011 Jul 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13805887
A dose of 2 mg levallorphan in combination with 100 mg pethidine repeated in an hour administered to women in labor
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9016350
Efficacy and potency of Levallorphan for stimulation of [35S]GTPγS binding to mMOR-CHO membranes was studied. Membranes were incubated incubated for 1 hr at 30° with various concentrations of levallorphan in the presence of 0.05 nm [35S]GTPγS and 10 uM GDP. EC50 of levallorphan was 2.7 nM. It was a partial agonist in these cells, producing ∼12% of the stimulation observed with DAMGO.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:59:52 GMT 2023
by
admin
on
Sat Dec 16 16:59:52 GMT 2023
|
Record UNII |
353613BU4U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C681
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00504
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
5359371
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
152-02-3
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
205-799-1
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
1560
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
353613BU4U
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
DTXSID9023205
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
100000082820
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
m6780
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | Merck Index | ||
|
C66004
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
7209
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
264
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
2148
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
CHEMBL1254682
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
D007977
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
6370
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB08452MIG
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY | |||
|
LEVALLORPHAN
Created by
admin on Sat Dec 16 16:59:52 GMT 2023 , Edited by admin on Sat Dec 16 16:59:52 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |